EU panel rejects Pfizer’s tanezumab for osteoarthritis painAny lingering hope that Pfizer’s may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor Share XEU panel rejects Pfizer’s tanezumab for osteoarthritis painhttps://pharmaphorum.com/news/eu-panel-rejects-pfizers-tanezumab-for-osteoarthritis-pain/
Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumabAfter more than a decade of fraught clinical development it looks like the end of the line for Share XThumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumabhttps://pharmaphorum.com/news/fda-experts-give-thumbs-down-for-pfizer-lillys-painkiller-tanezumab/
FDA starts review of Pfizer, Lilly’s non-opioid painkillerAfter years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, Share XFDA starts review of Pfizer, Lilly’s non-opioid painkillerhttps://pharmaphorum.com/news/fda-starts-review-of-pfizer-lillys-non-opioid-painkiller/
Pfizer/Lilly non-opioid pain drug shows more positive resultsResults from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can Share XPfizer/Lilly non-opioid pain drug shows more positive resultshttps://pharmaphorum.com/news/pfizer-lilly-non-opioid-pain-drug-shows-more-positive-results/
More positive results for Pfizer/Lilly’s non-opioid pain drugPfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain Share XMore positive results for Pfizer/Lilly’s non-opioid pain drughttps://pharmaphorum.com/news/more-positive-results-for-pfizer-lillys-non-opioid-pain-drug/
